125 related articles for article (PubMed ID: 23731537)
1. A recurrent PDGFRB mutation causes familial infantile myofibromatosis.
Cheung YH; Gayden T; Campeau PM; LeDuc CA; Russo D; Nguyen VH; Guo J; Qi M; Guan Y; Albrecht S; Moroz B; Eldin KW; Lu JT; Schwartzentruber J; Malkin D; Berghuis AM; Emil S; Gibbs RA; Burk DL; Vanstone M; Lee BH; Orchard D; Boycott KM; Chung WK; Jabado N
Am J Hum Genet; 2013 Jun; 92(6):996-1000. PubMed ID: 23731537
[TBL] [Abstract][Full Text] [Related]
2. Prenatal genetic diagnosis of disseminated infantile myofibromatosis: a case report and literature review.
Lü Y; Jiang Y; Wu H; Qi Q; Zhou X; Guo Q; Hao N; Liu J; Meng H
BMC Med Genomics; 2023 Aug; 16(1):185. PubMed ID: 37568122
[TBL] [Abstract][Full Text] [Related]
3. Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy.
Pattisapu P; Wenger TL; Dahl JP; Bly RA; Bonilla-Velez J; Wu N; Hall A; Rudzinski ER; Perkins JA
Clin Case Rep; 2022 Feb; 10(2):e05382. PubMed ID: 35154723
[TBL] [Abstract][Full Text] [Related]
4. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis.
Martignetti JA; Tian L; Li D; Ramirez MC; Camacho-Vanegas O; Camacho SC; Guo Y; Zand DJ; Bernstein AM; Masur SK; Kim CE; Otieno FG; Hou C; Abdel-Magid N; Tweddale B; Metry D; Fournet JC; Papp E; McPherson EW; Zabel C; Vaksmann G; Morisot C; Keating B; Sleiman PM; Cleveland JA; Everman DB; Zackai E; Hakonarson H
Am J Hum Genet; 2013 Jun; 92(6):1001-7. PubMed ID: 23731542
[TBL] [Abstract][Full Text] [Related]
5. PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.
Arts FA; Sciot R; Brichard B; Renard M; de Rocca Serra A; Dachy G; Noël LA; Velghe AI; Galant C; Debiec-Rychter M; Van Damme A; Vikkula M; Helaers R; Limaye N; Poirel HA; Demoulin JB
Hum Mol Genet; 2017 May; 26(10):1801-1810. PubMed ID: 28334876
[TBL] [Abstract][Full Text] [Related]
6. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Arts FA; Chand D; Pecquet C; Velghe AI; Constantinescu S; Hallberg B; Demoulin JB
Oncogene; 2016 Jun; 35(25):3239-48. PubMed ID: 26455322
[TBL] [Abstract][Full Text] [Related]
7. Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation.
Takenouchi T; Yamaguchi Y; Tanikawa A; Kosaki R; Okano H; Kosaki K
J Pediatr; 2015 Feb; 166(2):483-6. PubMed ID: 25454926
[TBL] [Abstract][Full Text] [Related]
8. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
Lee JW
Clin Genet; 2013 Oct; 84(4):340-1. PubMed ID: 23865785
[No Abstract] [Full Text] [Related]
9. A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome.
Johnston JJ; Sanchez-Contreras MY; Keppler-Noreuil KM; Sapp J; Crenshaw M; Finch NA; Cormier-Daire V; Rademakers R; Sybert VP; Biesecker LG
Am J Hum Genet; 2015 Sep; 97(3):465-74. PubMed ID: 26279204
[TBL] [Abstract][Full Text] [Related]
10. Infantile myofibromatosis.
Chung EB; Enzinger FM
Cancer; 1981 Oct; 48(8):1807-18. PubMed ID: 7284977
[TBL] [Abstract][Full Text] [Related]
11. Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG?
Linhares ND; Freire MC; Cardenas RG; Bahia M; Puzenat E; Aubin F; Pena SD
Genet Mol Res; 2014 Aug; 13(3):6287-92. PubMed ID: 25158255
[TBL] [Abstract][Full Text] [Related]
12. [Autosomal dominant (familial) infantile myofibromatosis: The causative role of mutations in PDGFRB and NOTCH3].
Dereure O
Ann Dermatol Venereol; 2013 Dec; 140(12):833-4. PubMed ID: 24315235
[No Abstract] [Full Text] [Related]
13. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.
Pond D; Arts FA; Mendelsohn NJ; Demoulin JB; Scharer G; Messinger Y
Genet Med; 2018 Jan; 20(1):142-150. PubMed ID: 28726812
[TBL] [Abstract][Full Text] [Related]
14. Infantile myofibromatosis: a series of 28 cases.
Mashiah J; Hadj-Rabia S; Dompmartin A; Harroche A; Laloum-Grynberg E; Wolter M; Amoric JC; Hamel-Teillac D; Guero S; Fraitag S; Bodemer C
J Am Acad Dermatol; 2014 Aug; 71(2):264-70. PubMed ID: 24894456
[TBL] [Abstract][Full Text] [Related]
15. Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis.
Dachy G; de Krijger RR; Fraitag S; Théate I; Brichard B; Hoffman SB; Libbrecht L; Arts FA; Brouillard P; Vikkula M; Limaye N; Demoulin JB
JAMA Dermatol; 2019 Aug; 155(8):946-950. PubMed ID: 31017643
[TBL] [Abstract][Full Text] [Related]
16. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Somatic PDGFRB Mutations in Sporadic Infantile/Solitary Adult Myofibromas But Not in Angioleiomyomas and Myopericytomas.
Agaimy A; Bieg M; Michal M; Geddert H; Märkl B; Seitz J; Moskalev EA; Schlesner M; Metzler M; Hartmann A; Wiemann S; Michal M; Mentzel T; Haller F
Am J Surg Pathol; 2017 Feb; 41(2):195-203. PubMed ID: 27776010
[TBL] [Abstract][Full Text] [Related]
18. Novel
Hassan M; Butler E; Wilson R; Roy A; Zheng Y; Liem P; Rakheja D; Pavlick D; Young LL; Rosenzweig M; Erlich R; Ali SM; Leavey PJ; Parsons DW; Skapek SX; Laetsch TW
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645346
[TBL] [Abstract][Full Text] [Related]
19. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
[TBL] [Abstract][Full Text] [Related]
20. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
